| TEST CHANGE |  |
| :---: | :---: |
| Congenital Adrenal Hyperplasia Panel, 21-Hydroxylase Deficiency |  |
| 2002283, CAH 21 HYDROX |  |
| Specimen Requirements: |  |
| Patient Preparation: | Collect between 6-10 a.m. |
| Collect: | Serum separator tube or green (sodium or lithium heparin). Also acceptable: Pink (K2EDTA). |
| Specimen Preparation: | Separate serum or plasma from cells ASAP or within 2 hours of collection. Transfer 1.8 mL serum or plasma to an ARUP Standard Transport Tube and freeze immediately. (Min: 0.9 mL ) |
| Transport Temperature: | CRITICAL FROZEN. Separate specimens must be submitted when multiple tests are ordered. |
| Unacceptable Conditions: | Refrigerated or room temperature specimens. |
| Remarks: |  |
| Stability: | After separation from cells: Ambient: Unacceptable; Refrigerated: Unacceptable; Frozen: 6 months |
| Methodology: | Quantitative High Performance Liquid ChromatographyTandem Mass Spectrometry |
| Performed: | Sun-Sat |
| Reported: | 1-54 days |
| Note: |  |
| CPT Codes: | 82157; 83498; 84143; 82626 |
| New York DOH Approval Status: | This test is New York DOH approved. |
| Interpretive Data: |  |
| This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes. |  |
| Reference Interval: |  |


| Test <br> Number | Remponents |  |  |  |
| :--- | :--- | :--- | :--- | :--- |
|  |  |  |  |  |



Androstenedione by TMS

|  | Age | Male ( $\mathrm{ng} / \mathrm{mL}$ ) | Female ( $\mathrm{ng} / \mathrm{mL}$ ) |
| :---: | :---: | :---: | :---: |
|  | Premature Infants (26-28 weeks Day 4) | 0.92-2.82 | 0.92-2.82 |
|  | Premature Infants (31-35 weeks Day 4) | 0.80-4.46 | 0.80-4.46 |
|  | Full Term Infants (1-7 days) | 0.20-2.90 | 0.20-2.90 |
|  | 8-30 days | 0.18-0.80 | 0.18-0.80 |
|  | 1-5 months | 0.06-0.68 | 0.06-0.68 |
|  | 6-24 months | 0.03-0.15 | Less than 0.15 |
|  | 2-3 years | Less than 0.11 | Less than 0.16 |
|  | 4-5 years | 0.02-0.17 | 0.02-0.21 |
|  | 6-7 years | 0.01-0.29 | 0.02-0.28 |
|  | 8-9 years | 0.03-0.30 | 0.04-0.42 |
|  | 10-11 years | 0.07-0.39 | 0.09-1.23 |
|  | 12-13 years | 0.10-0.64 | 0.24-1.73 |
|  | 14-15 years | 0.18-0.94 | 0.39-2.00 |
|  | 16-17 years | 0.30-1.13 | 0.35-2.12 |
|  | 18-39 years | 0.33-1.34 | 0.26-2.14 |
|  | 40 years and older | 0.23-0.89 | 0.13-0.82 |
|  | Premenopausal | Not Applicable | 0.26-2.14 |
|  | Postmenopausal | Not Applicable | 0.13-0.82 |
|  | Tanner Stage I | 0.04-0.32 | 0.05-0.51 |
|  | Tanner Stage II | 0.08-0.48 | 0.15-1.37 |
|  | Tanner Stage III | 0.14-0.87 | 0.37-2.24 |
|  | Tanner Stage IV-V | 0.27-1.07 | 0.35-2.05 |
| Dehydroepiandrosterone by TMS |  |  |  |



